This chapter explores the drug discovery efforts of 23andMe and their focus on immuno-oncology. It discusses the challenges in drug development, the high failure rate in the industry, and the potential of leveraging human genetics and AI to improve drug discovery. The chapter also touches on the role of regulation in drug discovery and gene editing, as well as the need for thoughtful consideration and discussion regarding the consequences of technologies like CRISPR.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode